Reunión Clínica Septiembre 2021

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Diabetes & Endocrinology Vol 9: 586–594  Kosiborod M, Esterline R, Furtado M, Oscarsson J, Gasparyan S, Koch G and othersdoi.org/10.1016/S2213-8587(21)00180-7

Screening for Prediabetes and Type 2 Diabetes US Preventive Services Task Force Recommendation Statement US Preventive Services Task ForceJAMA. 2021;326(8):736-743doi.org/10.1001/jama.2021.12531